 MARSEILLE, France, Dec. 11, 2020 GLOBE NEWSWIRE -- Innate Pharma SA Euronext Paris: IPH ISIN: FR0010331421; Nasdaq: IPHA Innate or the Company today announced that it will return the US and EU commercialization rights of Lumoxiti moxetumomab pasudotox-tdfk to AstraZeneca1. Innate licensed the US and EU rights to AstraZenecas FDA-approved Lumoxiti for certain patients with relapsed or refractory hairy cell leukemia in October 2018. 